Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan 1;322(1):E54-E62.
doi: 10.1152/ajpendo.00260.2021. Epub 2021 Nov 22.

Novel effects of the gastrointestinal hormone secretin on cardiac metabolism and renal function

Sanna Laurila  1   2   3 , Eleni Rebelos  1 , Minna Lahesmaa  1   4 , Lihua Sun  1 , Katharina Schnabl  5   6   7 , Tia-Mari Peltomaa  1 , Riku Klén  1 , Mueez U-Din  8 , Miikka-Juhani Honka  1 , Olli Eskola  1 , Anna K Kirjavainen  1 , Lauri Nummenmaa  1   9 , Martin Klingenspor  5   6   7 , Kirsi A Virtanen  8   10   11 , Pirjo Nuutila  1   12
Affiliations
Randomized Controlled Trial

Novel effects of the gastrointestinal hormone secretin on cardiac metabolism and renal function

Sanna Laurila et al. Am J Physiol Endocrinol Metab. .

Abstract

The cardiac benefits of gastrointestinal hormones have been of interest in recent years. The aim of this study was to explore the myocardial and renal effects of the gastrointestinal hormone secretin in the GUTBAT trial (NCT03290846). A placebo-controlled crossover study was conducted on 15 healthy males in fasting conditions, where subjects were blinded to the intervention. Myocardial glucose uptake was measured with [18F]2-fluoro-2-deoxy-d-glucose ([18F]FDG) positron emission tomography. Kidney function was measured with [18F]FDG renal clearance and estimated glomerular filtration rate (eGFR). Secretin increased myocardial glucose uptake compared with placebo (secretin vs. placebo, means ± SD, 15.5 ± 7.4 vs. 9.7 ± 4.9 μmol/100 g/min, 95% confidence interval (CI) [2.2, 9.4], P = 0.004). Secretin also increased [18F]FDG renal clearance (44.5 ± 5.4 vs. 39.5 ± 8.5 mL/min, 95%CI [1.9, 8.1], P = 0.004), and eGFR was significantly increased from baseline after secretin, compared with placebo (17.8 ± 9.8 vs. 6.0 ± 5.2 ΔmL/min/1.73 m2, 95%CI [6.0, 17.6], P = 0.001). Our results implicate that secretin increases heart work and renal filtration, making it an interesting drug candidate for future studies in heart and kidney failure.NEW & NOTEWORTHY Secretin increases myocardial glucose uptake compared with placebo, supporting a previously proposed inotropic effect. Secretin also increased renal filtration rate.

Keywords: gastrointestinal hormone; kidney function; myocardial metabolism; secretin.

PubMed Disclaimer

Conflict of interest statement

M.K. is an inventor on a patent application from the Technical University of Munich (Publication No. WO/2017/20285; International Application No. PCT/EP2017/062420) addressing the role of secretin receptor agonists and modulators in the regulation of energy homeostasis. This patent is based on the initial discovery that meal-induced secretin inhibits food intake, and this anorexigenic action of secretin depends on the activation of brown fat (6). None of the other authors has any conflicts of interest, financial or otherwise, to disclose.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Overview of the scanning protocol. Two PET/CT scans were conducted in fasting conditions, in a single-blinded and randomized order, with a placebo (saline) and secretin (secretin pentahydrochloride 1 IU/kg *2) intervention. Arrows indicate the timing of intravenous secretin/placebo infusions. [18F]FDG (150 MBq) was injected at 20 min, after which PET scanning of the neck, and then the thoracic region, was initiated. Indirect calorimetry was conducted for 2 h. Timing of arterialized samples is indicated with test tube figures. Twelve-lead ECG was collected at timepoints 0, 60 and 120 min. CT, computed tomography; [18F]FDG, [18F]2-fluoro-2-deoxy-d-glucose.
Figure 2.
Figure 2.
Myocardial glucose uptake results. A: representative [18F]FDG PET/CT vertical long axis images showing Ki of the heart after secretin and placebo infusions (n = 1). Short axis images are shown in Supplemental Fig. S1. (see https://doi.org/10.6084/m9.figshare.16912807). B: the effect of secretin infusion on myocardial glucose uptake compared with placebo (n = 15). Data were analyzed by Student’s paired t test. C: whole body carbohydrate oxidation (CHO) correlates with myocardial glucose uptake (MGU) after secretin administration (n = 15). Data were analyzed by Pearson correlation. A line has been drawn on the data to indicate a significant association whereas dotted curves represent confidence interval. CT, computed tomography; [18F]FDG, [18F]2-fluoro-2-deoxy-d-glucose.
Figure 3.
Figure 3.
Organ glucose uptake correlations (n = 15). A: brown adipose tissue glucose uptake is strongly associated with myocardial glucose uptake after secretin infusion, while no association is seen during placebo (B). C: skeletal muscle glucose uptake is not associated with myocardial glucose uptake after secretin infusion, while an association exists during placebo (D). Data were analyzed by Pearson correlation. A line has been drawn on the data to indicate a significant association whereas dotted curves represent confidence interval. All units are μmol/100 g/min.
Figure 4.
Figure 4.
Renal function results. A: secretin decreases serum creatinine compared with placebo (n = 10). Values were normalized, dividing by the value of the first time point. Mean values and standard error are shown on graph. Each timepoint was analyzed by paired Wilcoxon signed-rank test. The secretin intervention is shown in orange whereas the placebo intervention is shown in gray. B: eGFR, calculated by Cockroft–Gault equation, was increased by secretin from baseline at 30 minutes, compared with placebo (n = 10). C: [18F]FDG renal clearance was increased after secretin (n = 15). B and C: data were analyzed by Student’s paired t test. [18F]FDG, [18F]2-fluoro-2-deoxy-d-glucose; eGFR, estimated glomerular filtration rate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41: 255–323, 2020. doi:10.1093/eurheartj/ehz486. - DOI - PubMed
    1. Nauck MA, Meier JJ, Cavender MA, El Aziz MA, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136: 849–870, 2017. doi:10.1161/CIRCULATIONAHA.117.028136. - DOI - PubMed
    1. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 28: 325–353, 1902. doi:10.1113/jphysiol.1902.sp000920. - DOI - PMC - PubMed
    1. Kim MS, Lee KY, Chey WY. Plasma secretin concentrations in fasting and postprandial states in dog. Am J Physiol Endocrinol Physiol 5: E539–E544, 1979. doi:10.1152/ajpendo.1979.236.5.e539. - DOI - PubMed
    1. Laurila S, Sun L, Lahesmaa M, Schnabl K, Laitinen K, Klén R, Li Y, Balaz M, Wolfrum C, Steiger K, Niemi T, Taittonen M, U-Din M, Välikangas T, Elo LL, Eskola O, Kirjavainen AK, Nummenmaa L, Virtanen KA, Klingenspor M, Nuutila P. Secretin activates brown fat and induces satiation. Nat Metab 3: 798–809, 2021. doi:10.1038/s42255-021-00409-4. - DOI - PubMed

Publication types

MeSH terms